Implementing USP <800>: Personal Protective Equipment Requirements
Occupational exposure to hazardous drugs has been an increasing concern as this exposure can be associated with negative health effects such as skin rashes, decreased fertility, spontaneous abortions, congenital malformations, and cancers. Although these risks are well defined, the practical application and implementation of personal protective equipment requirements as outlined in USP General Chapter <800> can be challenging due to various obstacles, including financial limitations, lack of knowledge and competency, and resistance to change. During this webinar you will learn how to address these challenges by applying the National Institute for Occupational Safety and Health (NIOSH) groupings of hazardous drugs and the recommendations for personal protective equipment. This approach stratifies personnel risk by taking into account the toxicokinetics of the drug, the dosage form, and the types of handling activities performed. This risk stratification allows for more practical guidance on personal protective equipment such that full implementation is more tangible and meaningful. With this, a greater compliance can be achieved.
Note to California pharmacists: The personal protective equipment requirements discussed in this webinar are also applicable to California Board Of Pharmacy (BOP) regulations even though the regulations do not adopt USP <800> in its entirety. Personal protective equipment required for antineoplastic drugs will be covered.
Please note: You will receive 1.00 non-accredited Contact Hour upon completion of the webinar.
- Pharmacy Managers
- Understand the health risks associated with occupational exposure to hazardous drugs.
- Describe the personal protective equipment requirements outlined in USP General Chapter <800> and NIOSH standards.
- Select personal protective equipment based on the NIOSH tiered approach.
- Outline donning and doffing procedures.
- Provide strategies to ensure staff compliance with personal protective equipment.
High speed internet connectivity and an updated internet browser is required to attend the webinar. The broadband recommended is 1 Mbps or better. The minimum browser requirements to attend the webinar are:
- Google Chrome v39 or later
- Mozilla Firefox v34 or later
- Internet Explorer v8 or later
- Microsoft Edge
- Apple Safari v6 or later
CHRISTINE ROUSSEL, PharmD, BCOP, BCSCP
Dr. Christine Roussel is a Board Certified Oncology Pharmacist Board Certified Sterile Compounding Pharmacist with a bachelor's in Toxicology and doctorate in Pharmacy from Philadelphia College of Pharmacy. She is Director of Pharmacy at Doylestown Hospital (Pennsylvania), Adjunct Assistant Professor at USciences, Facilitator for LP3 Network, and consultant for MEDISCA Network. On top of her day job of overseeing the clinical and operational aspects of patient care, she provides over 100 hours of education to pharmacists, pharmacy technicians, physicians, and nurses each year.
Dr. Roussel focuses on occupational exposure to hazardous drugs, sterile/non-sterile compounding, clinical and legislative topics, such as medical cannabis, opioid stewardship, drug diversion prevention, pharmaceutical waste and contamination. She is a consultant for cleanroom facility design. She has authored articles on occupational exposure to hazardous drugs, as protecting healthcare providers’ DNA is her primary passion! Her most recent publication is: Meta-analysis of chromosomal aberrations as a biomarker of exposure in healthcare workers occupationally exposed to antineoplastic drugs. In 2018 she was nationally recognized as “40 Under 40 in Oncology”
She is active in many professional organizations, including Delegate for the American Society of Health Systems Pharmacy, President of the Pennsylvania Society of Health Systems Pharmacy, Board of Directors for International Society of Cannabis Pharmacists, American Industrial Hygiene Association, and the Association for Compounding Pharmacists (ACP).
CANCELLATION AND REFUND POLICY:
There are no refunds, returns or transfer upon purchase of the webinar.